Abstract Introduction VACTERL is an uncommon association of congenital anomalies that stands for vertebral defects, anal atresia, cardiac defects, tracheoesophageal fistula, renal anomalies, and limb abnormalities. In addition to these classical features, patients may present with airway abnormalities such as bronchial stenosis or bronchomalacia, which can lead to significant respiratory compromise. Severe bronchial stenosis is usually treated with open airway reconstruction or lung transplantation; however, this is associated with substantial risks, especially in patients with complicated congenital conditions. Interventional bronchoscopic techniques, such as paclitaxel-coated balloon dilatation, allow a less invasive alternative for restoring airway patency and reducing restenosis. We describe the case of a patient with VACTERL association and severe bronchial stenosis successfully treated with serial paclitaxel-coated balloon dilatations, avoiding the need for lung transplantation. Case description A 27-year-old male with VACTERL association presented with symptomatic left mainstem bronchial stenosis and complete right lung collapse. Bronchoscopic intervention was performed over lung transplantation because of the patient’s young age and high surgical risk. It revealed complete fibrotic obstruction of the right main bronchus and proximal stenosis of the left mainstem bronchus, measuring approximately 5-6 mm in diameter. Performing paclitaxel-coated balloon dilation showed progressive airway enlargement and clinical improvement. Under bronchoscopic guidance using a drug-coated balloon (diameter 8-10 mm, length 40 mm), which was placed in the narrowed segment and inflated for 2 minutes to expand the airway and deliver paclitaxel locally, thereby inhibiting cell proliferation and scar tissue formation. Subsequent follow-ups showed that the left mainstem bronchus diameter increased to 8-9 mm, with improvement in the airway patency and respiratory function, without any significant complications. Discussion Although the use of paclitaxel-coated balloon dilation for bronchial stenosis is still limited, this case illustrates its potential benefits as an adjunctive interventional therapy in patients with VACTERL association. The serial dilatations resulted in a progressive, sustained increase in airway diameter, from an initial 5-6 mm to approximately 8-9 mm at final follow-up in our patient (Figure 1). Compared with lung transplant, this intervention offers lower complication rates and the avoidance of chronic graft rejection and immunological complications, which are particularly relevant for young patients. This case report shows the potential of paclitaxel-coated balloon dilation as a safe, effective, and minimally invasive therapeutic option for managing bronchial stenosis in patients with complicated congenital disorders. This abstract is funded by: None
D24-15 Custom Y-stent Utilization in a Unique Tracheobronchomalacia Patient
Abstract Introduction Custom stents are a fast-evolving and revolutionary therapy for use in patients who require therapeutic stenting options due to a variety of tracheal, bronchial, and parenchymal diseases. The combination of increasing high-resolution CT imaging with 3-D printing technology has allowed for even greater flexibility in therapeutic treatment. Returned mesh is a well-described phenomenon in the medical literature and can create a wide variety of difficult to manage complications. Description The patient is a 64-year-old male with a past medical history of tracheobronchomalacia status post tracheoplasty with prolene mesh placement in April 2011 which was complicated by erosion of mesh through the membranous airway in April 2017. He subsequently underwent a right thoracotomy with a muscle flap reconstruction of the membranous trachea in May 2017. This was then complicated by a diverticulum of the distal trachea that was non-communicative with the esophagus and chronic stenosis of the left mainstem bronchus with residual mesh retained in the posterior membranous left mainstem bronchus. He had a custom Y-stent placed for the first time in February 2022 due to persistent sensation of shortness of breath along with productive cough. He experienced immediate relief after placement of his custom stent and has since demonstrated remarkable stability, rarely requiring unscheduled bronchoscopy for mucous clearance. He has nonetheless derived immense benefit from stenting from a symptomatic standpoint since initial placement in 2022. Discussion Customized stents utilizing 3-D printing technology have allowed far more flexibility to the clinical approach of patients with complex airway pathology. As tracheal and bronchial reconstruction surgeries continue to involve more complicated management modalities, including the use of mesh, complications will continue to arise. Mesh erosion is a potentially devastating complication from tracheobronchoplasty. It will, therefore, be important to facilitate treatment of complications from these and other modalities. Therapeutic bronchoscopy with custom stent placement will almost certainly continue to evolve as an effective tool in the management of patients such as these. This abstract is funded by: None
C79-06 Robotic Assisted Bronchoscopy With Endobronchial Pulsed Electric Field Ablation Behind an Obstructed Airway
Abstract Introduction Pulsed Electric Field (PEF) Ablation has been used as an adjunct therapy for cancer. Robotic-Assisted Bronchoscopy (RAB) enables precise access to pulmonary lesions for biopsy and ablative therapy. However, anatomic obstructions within the airway may prohibit access to peripheral targets. We report a case in which robotic bronchoscopy navigation for the delivery of PEF was not initially possible due to a new anatomic airway obstruction secondary to radiation fibrosis. We were able to utilize therapeutic bronchoscopy to re-cannulate the airway and deliver the PEF via the robotic bronchoscope. Case Report A 68-year-old man with a history of left lung adenocarcinoma was treated with surgery, chemoradiation and durvalumab consolidation therapy. Surveillance imaging 4 years later revealed consolidation in the right upper mediastinum. A bronchoscopy brush biopsy confirmed adenocarcinoma and received systemic chemotherapy. Later a PET-CT showed a non FDG avid enlarged right paratracheal lesion. Follow-up CT revealed complete obstruction of the right middle lobar bronchus with associated middle lobe collapse likely secondary to radiation. Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) of the right paratracheal lesion confirmed malignancy on onsite cytopathology. Subsequently, we performed two PEF ablations targeting the involved lesion. Repeat PET-CT demonstrated two hypermetabolic foci in the right hilum and right supraclavicular region. However, the previously PEF treated paratracheal lesion was not PET avid. We used a RAB to navigate into the right upper lobe and identified the anterior segment to be obstructed in addition to the previously noted right middle lobe. Due to this, the robotic bronchoscope couldn’t be advanced to the right hilar PET avid lesion. Utilizing guidewires, balloon dilatation and fluoroscopy we re-cannulated the obstructed right upper lobe segment and subsequently advance the robotic bronchoscope to the target in the right upper lobe. Under cone-beam guidance, multiple biopsies were obtained and confirmed as malignant. Following this, the INUMI PEF needle was deployed. We delivered two PEF activations to the right hilar PET-avid lesion. Subsequent systemic staging using linear EBUS identified station 4R lymph node involvement, positive for malignancy on rapid onsite cytopathologic evaluation. The 4R lymph node was superior to the previously treated paratracheal lesion. We then deployed the INUMI PEF needle, and PEF ablation was performed successfully. Discussion To our knowledge, this is the first reported instance of combining robotic and therapeutic bronchoscopy to overcome airway obstruction to facilitate the distal treatment of peripheral target with PEF. This abstract is funded by: None
C79-04 NUT Carcinoma-induced Central Airway Obstruction Treated With Pulsed Electric Field Ablation
Abstract Introduction Nuclear protein in testis (NUT) carcinoma, formerly known as NUT midline carcinoma, is a rare and highly aggressive subtype of squamous cell carcinoma characterized by NUTM1 gene rearrangements. It typically affects children and young adults and shows a predilection for midline structures of the head, neck, and thorax. We describe a rare case of NUT carcinoma in an elderly patient presenting with central airway obstruction treated with tumor debulking, devascularization, and pulsed electric field (PEF) ablation. Case An 89-year-old woman on chronic anticoagulation for atrial fibrillation presented with respiratory distress and hemoptysis requiring intubation and mechanical ventilation. Chest CT revealed a developing right lower lobe infiltrate and bronchoscopy demonstrated a non-obstructing right lower lobe endobronchial lesion. Pathology of the lesion confirmed NUT carcinoma but the patient was lost to follow-up. Two months later, she presented with altered mental status and respiratory failure. Imaging revealed a 4.6 x 2.6 cm mass at the level of the cricoid cartilage causing approximately 75% tracheal obstruction with tracheal wall invasion. She underwent rigid bronchoscopy with tumor debulking and devascularization, achieving >80% tracheal patency post-procedure. EBUS-guided PEF ablation was then performed to target residual bulky tumor found in the paratracheal area. Given her age, comorbidities, and poor performance status, palliative chemotherapy was deferred and palliative radiotherapy was offered to limit tumor progression. Discussion NUT carcinoma is a rare and aggressive malignancy with a poor prognosis. This case demonstrates rapid tumor progression leading to respiratory failure within two months of initial diagnosis. Management options for malignant central airway obstruction in non-surgical candidates may include endobronchial debulking and ablative therapies. In this case, EBUS-guided PEF ablation, a non-thermal technique that delivers brief electric pulses to induce tumor apoptosis while sparing adjacent structures, was successfully used to treat residual disease with the goal of reducing marginal regrowth and maintain airway patency. PEF ablation has been described in percutaneous and bronchoscopic management of early stage non-small cell lung cancer; however, its application in central airway obstruction represents an innovative therapeutic approach. Although chemoradiation may be considered when feasible, no standard regimen exists for NUT carcinoma. It typically responds poorly to conventional therapies, underscoring the importance of complementary local treatment strategies in select patients. This case highlights the rapidly progressive course of NUT carcinoma and demonstrates the potential role of PEF ablation as a novel adjunct in the palliative management of malignant central airway obstruction. This abstract is funded by: None
C44-26 Robotic-assisted Bronchoscopy for Fungal Lung Infections: Overcoming the Diagnostic Limitations of Bronchoalveolar Lavage (BAL) Antigen Testing
Abstract Introduction The diagnosis of fungal lung infections remains challenging as standard tests, such as bronchoalveolar lavage (BAL) antigen testing, often yield variable or inconclusive results. These limitations can delay appropriate therapy and may require additional tissue sampling for definitive diagnosis. Robotic-assisted bronchoscopy (RAB) biopsy has been primarily used as a minimally invasive technique for assessing suspicious peripheral pulmonary lesions (PPL). This case series highlights the diagnostic utility of RAB for identifying fungal infections within PPL when conventional BAL antigen analysis is non-diagnostic. Case Description Four patients with suspected infectious or malignant PPL underwent RAB-guided biopsy for diagnostic clarification, all yielding histopathologic confirmation of fungal disease. The first, a 73-year-old bilateral lung-transplant recipient with hemoptysis, had a negative BAL Aspergillus antigen despite RAB biopsy confirming Aspergillus infection. Similarly, a second 73-year-old man with chronic obstructive pulmonary disease (COPD) and esophageal adenocarcinoma had a negative BAL antigen, while RAB biopsy of bilateral cavitary lesions confirmed Aspergillus. Additionally, a 39-year-old woman with a nodule being evaluated for malignancy, had negative BAL Histoplasma antigen and PCR, whereas RAB biopsy confirmed Histoplasma capsulatum. In contrast, a 56-year-old woman with a right-lower-lobe nodule had a positive BAL Aspergillus antigen that aligned with the histopathologic biopsy findings. Discussion BAL-based antigen testing demonstrates variable diagnostic accuracy in fungal lung disease. Reported sensitivities for Aspergillus detection are typically high in meta-analysis, approximately 80%-90%, but clinical performance in the immunocompromised or high-risk patients is often substantially lower. Similarly, while BAL antigen testing for Histoplasma performs well in disseminated infections, it often fails to detect localized pulmonary disease. In this series, three out of four patients had negative BAL results in the presence of histopathologic confirmation of fungal infection. While current guidelines consider BAL positivity supportive of a “probable” diagnosis, tissue histopathology remains the gold standard for a “proven” infection. These findings emphasize the value and capability of RAB in obtaining direct tissue confirmation when conventional testing, such as BAL antigen analysis, is non-diagnostic. Conclusion RAB-guided biopsy of PPLs offers the opportunity for histopathologic confirmation of fungal infection when BAL testing is non-diagnostic. This approach can enhance upfront diagnostic yield in patients with suspected fungal pulmonary infections, avoiding delays in diagnosis and treatment initiation. This abstract is funded by: None
C44-22 Unmasking the Leads: Pacemaker-induced Superior Vena Cava Syndrome Presenting as Bilateral Pleural Effusions
Abstract Introduction Superior vena cava (SVC) syndrome results from the obstruction or occlusion of the SVC, leading to a range of complications depending on severity, location, and chronicity with the development of collateral circulation. We present a case of a patient with prior facial edema and subsequent development of bilateral pleural effusions whose evaluation led to discovery of SVC stenosis and occlusion of bilateral brachiocephalic veins, likely related to chronic indwelling pacemaker leads. Case Report A 73-year-old woman with bileaflet mitral valve prolapse with mild-to-moderate regurgitation, sinus node dysfunction status post pacemaker placement in 2014, atrial fibrillation and an unprovoked extensive right upper extremity deep venous thrombosis (DVT) managed on chronic apixaban therapy presented to clinic for evaluation of bilateral pleural effusions. One year prior to presentation, she developed facial and supraclavicular edema with positional dyspnea. A CT head and neck did not explain her abrupt facial edema though showed a left-sided pleural effusion, which was addressed locally with serial thoracenteses followed by tunneled pleural catheter placement. This ultimately led to discomfort without improvement in dyspnea, prompting catheter removal. She later developed a right-sided pleural effusion and underwent thoracentesis with the fluid analysis shown in Table 1. Physical exam was notable for collateral vessels along the chest wall and abdomen. The collateral vessels, unexplained pleural effusions, prior extensive right upper extremity DVT, and history of now resolved facial edema prompted CT venogram; this revealed occlusion of the right and left brachiocephalic veins and severe narrowing of the SVC with venous collaterals noted. PET-CT showed no evidence of malignancy. Electrophysiology consultation attributed the SVC stenosis to the indwelling pacemaker leads. The patient underwent SVC cavogram with successful angioplasty across right internal jugular vein down to the SVC with improvement in pressure gradient. After recanalization, there was no significant reaccumulation of pleural effusions on follow up and patient’s dyspnea improved. Discussion Pleural effusions in the setting of SVC syndrome have been described, most commonly due to thrombosis, device-related complications, or malignancy. This case highlights the importance of considering device-related vascular complications in patients with unexplained pleural effusions, particularly those with a history of intrathoracic devices or procedures. Management should target the underlying cause of the effusion; however long-term data on outcomes and optimal management strategies for pacemaker-related SVC syndrome remain limited. This abstract is funded by: None
C23-22 Catheter Directed Thrombolysis Versus Systemic Therapy in Pulmonary Embolism: A Decade of Experience From the National Inpatient Sample (2010-2021)
Abstract Rationale High and intermediate risk pulmonary embolism (PE) contributes significantly to in hospital morbidity and 5-10% of in hospital deaths. Thrombolytic therapy either via systemic intravenous tissue plasminogen activator (IV-tPA) or catheter directed thrombolysis (CDT) remains central to management, however, comparative national data on utilization and outcomes of thrombolytic therapy for PE remain limited. Methods Using the National Inpatient Sample data from 2010 to 2021, adult hospitalizations for acute PE were identified using ICD 9 code 415.1 and ICD 10 code I26. Cases receiving IV-tPA or CDT were identified using procedural codes. Temporal trends, in-hospital mortality, length of stay (LOS) and complications were compared between treatment groups using weighted analyses. Results Among 1,940,718 hospitalizations with acute pulmonary embolism, the use of thrombolytic therapy increased from 2010 to 2021 for both systemic intravenous tissue plasminogen activator (IV-tPA) and catheter-directed thrombolysis (CDT). Utilization of IV-tPA rose from 1.8% to 2.%, while CDT increased from 1.4% to 3.9%. Compared to IV-tPA, patients treated with CDT were more likely to be older (42.7% vs 39.3% were aged 65 years or above) and male (50.8% vs 48.7%). CDT was associated with significantly lower in hospital mortality (6.7% versus 11.1%, p < 0.01), shorter median length of stay (5 versus 6 days, p < 0.01) and fewer discharges to facilities (13.7% versus 19.4 %, p < 0.01). Rates of major complications were lower in the CDT group, including intracranial hemorrhage (0.4% versus 1.2%), cardiac arrest (1.7% versus 7.3%), myocardial infarction (4.7% versus 5.1%) and need for mechanical ventilation (6.7% versus 16.1%). However, use of extracorporeal membrane oxygenation (0.7% versus 0.2 %) and surgical embolectomy (1.2% versus 0.7%) was higher among CDT patients. Conclusions From 2010 to 2021, utilization of thrombolytic therapy, particularly catheter-directed techniques increased among PE hospitalizations. CDT was associated with lower in hospital mortality, shorter stays and fewer complications compared to systemic IV-tPA. These findings support the expanding role of catheter based interventions as a preferred therapeutic approach for patients with high and intermediate risk pulmonary embolism. Further prospective studies are warranted to confirm long term outcomes and optimize patient selection for CDT. This abstract is funded by: None
B46-23 A Phantom Mediastinal Mass -Pericardial Recess
Abstract Introduction Mediastinal masses encompass broad differentials of reactive, inflammatory, infectious or neoplastic etiology. In the background of extra thoracic malignancy, it raises a high suspicion for primary cancer or metastatic lymphadenopathy. However, a benign anatomical variant can mimic these findings and lead to unnecessary diagnostic procedures and patient anxiety. Recognizing mimickers becomes crucial in avoiding misdiagnosis and overtreatment. Case A 50-year-old woman with no significant past medical history presented with a two-day history of headache, associated with cough, orthopnea and lower extremity edema. Vital signs were significant for elevated blood pressure at 199/107 mm Hg. Laboratory findings noted a markedly elevated B-type natriuretic peptide (19,000 pg/mL), increased serum creatinine (1.4 mg/dL from baseline 0.7 mg/dL) and proteinuria. Chest X-ray revealed pulmonary vascular congestion. Autoimmune serologies were positive for antinuclear antibody (titer 1:2560), ribonucleoprotein antibody, and RNA polymerase III antibody. Renal biopsy confirmed scleroderma renal crisis. She was treated for hypertensive emergency secondary to scleroderma renal crisis. Further evaluation for elevated total protein revealed monoclonal gammopathy on electrophoresis and 30% plasma cells on bone marrow biopsy, consistent with smoldering multiple myeloma. A chest computed tomography scan incidentally identified a 4 × 3 cm lobular right paratracheal mass. Tissue biopsy was requested to exclude plasmacytoma. Bronchoscopy with endobronchial ultrasound revealed a large hypoechoic paratracheal lesion. Biopsy was aborted due to its cystic appearance and risk of airway flooding. Subsequent magnetic resonance imaging was obtained for tissue characterization which delineated the mass as a thin walled, fluid filled structure communicating with the superior aortic recess, consistent with a high riding superior pericardial recess which is a benign anatomical variant. She was discharged with plans for outpatient multidisciplinary follow up, including pulmonary evaluation for interstitial lung disease surveillance. Discussion High riding pericardial recess is a benign anatomical variant which can closely mimic pathologic masses or lymphadenopathy on cross sectional imaging. Key is identification of probable communication with the superior aortic recess associated with fluid attenuation. Knowledge of anatomy, comprehensive multimodal imaging review, and multidisciplinary discussion are key to prevent unnecessary investigation of mediastinal abnormalities. This abstract is funded by: None
A45-07 Predictors of Response and Complications After Endobronchial Valve Placement in Advanced Emphysema: A Single-Center Cohort Study
Abstract Rationale Endobronchial valve (EBV) placement is an established bronchoscopic lung volume reduction (BLVR) therapy for advanced emphysema. Although randomized trials have shown improvements in lung function, real-world data on predictors of response and complications remain limited. This study evaluated physiological and clinical outcomes after EBV placement and explored predictors of treatment response and adverse events. Methods We retrospectively analyzed 75 patients who underwent EBV placement for severe emphysema at Mayo Clinic Florida between 2018 and 2023. Demographics, comorbidities, pulmonary function test and complications data were collected before and after procedure. Responders were defined as those achieving a ≥ 15% relative increase in forced expiratory volume in one second (FEV1), ≥10% reduction in residual volume (RV), ≥25-meter increase in six-minute walk distance (6MWD), or ≥ 1-point decrease in modified Medical Research Council (mMRC) dyspnea score. Results The mean age was 70.4 ± 7.1 years, 59% were female, and the mean Body Mass Index was 25.6 ± 4.9 kg/m². Most patients were non-Hispanic White (96%) and ever-smokers (97%, median 40 pack-years). Following EBV placement, FEV1 increased by + 0.10 L (p < 0.001), forced vital capacity by + 0.17 L (p = 0.001), RV decreased by -0.69 L (p < 0.001), while total lung capacity decreased by -0.35 L (p < 0.001). Diffusing capacity, 6MWD, and mMRC did not significantly change. Responder analysis showed FEV1 improvement in 52% (34/65), RV reduction in 65% (42/65), 6MWD gain in 33% (18/55), and mMRC improvement in 33% (21/63). Complete lobar atelectasis occurred in 59% (44/75) and was significantly associated with FEV1 improvement (p < 0.01). 30-day follow up complications included pneumothorax (26.7%), COPD exacerbation (21%), and pneumonia (20%). 15% pneumothoraces were managed conservatively, 55% required chest tube, 30% needed valve removal due to persistent air leak. Valve migration and replacement occurred in 2.6% each, and valve removal in 26.6% patients. Median hospital stay was longer in patients with complications (5 vs 4 days, p = 0.003). In-hospital mortality was 5.3% but no procedure-related deaths were identified. Conclusions EBV placement is a safe and effective BLVR approach yielding significant improvements in FEV1 and reductions in hyperinflation. Pneumothorax and valve-related events were the most frequent complications. Complete lobar atelectasis strongly correlated with functional improvement, suggesting that early reassessment should be considered when collapse is not achieved to prevent complications and unnecessary valve retention. This abstract is funded by: None
A21-05 Multicenter Bronchoscopic Assessment of Multifocal Peripheral Pulmonary Nodules: The MULTIBRANCH Study
Abstract Rationale Advances in bronchoscopic technology, including robotic-assisted bronchoscopy (RaB) and cone-beam CT (CBCT), have enabled biopsy of multiple nodules in a single procedure. Here we present the procedural characteristics, safety, diagnostic yield, and use of linear endobronchial ultrasound (EBUS) staging in patients with multifocal pulmonary nodules biopsied under a single anesthesia event. Methods This multi-center, retrospective observational study included adults undergoing RaB biopsy of multifocal peripheral pulmonary lesions and lymph node assessment under a single anesthesia event at six U.S. centers from 11/2019 - 8/2025. Procedures utilized either the Ion (Intuitive) or Monarch (Ethicon) systems under general anesthesia. De-identified demographic, radiologic, procedural, pathologic, and safety data were collected in a secure centralized database. Safety outcomes included pneumothorax and its sequelae, hypoxia, and infectious complications. Diagnostic yield was determined using the 2024 ATS/ACCP consensus statement. NGS adequacy was reported from two health systems with well-defined criteria for sufficiency and standard institutional practices for sending NGS testing on both nodules. Statistical analyses utilized included descriptive statistics, t-tests, chi-squared/Fisher’s tests where appropriate, and logistic regression. Results Among 191 patients, 177 underwent biopsy of two and 14 of three nodules. Lymph nodes were sampled in 167 (87.4%), with 18 (10.8%) positive for malignancy; notably, 17 of 18 (94%) patients with nodal metastases had at least one fully solid nodule. Complications occurred in 20 patients (10.5%), including pneumothorax in 14 (7.3%), with 4 (2.1%) requiring tube thoracostomy. There were no cases of bilateral pneumothorax. Transient hypoxia occurred in 3 patients (1.6%) and 3 developed outpatient-managed bronchitis. Seven patients (3.7%) required unplanned admission. Overall diagnostic yield was 72.2%, with 122 (63.9%) patients having two diagnostic nodules and 33 (17.4%) having two non-diagnostic nodules. Bronchus sign (OR 2.9, p = 0.003), radial EBUS use (OR 2.6, p = 0.025), and CBCT use (OR 2.4, p = 0.021) were associated with procedures having two diagnostic nodules. At sites with standardized NGS adequacy reporting, 74 of 81 malignant nodules (91%) provided sufficient tissue for NGS. Conclusions •Single-procedure biopsy of multifocal pulmonary nodules is feasible, safe, and achieves industry-standard strict diagnostic yield. •Complications are slightly higher than single-nodule procedures. Serious events were rare. •17 of 18 patients with malignant nodal disease had at least one fully solid nodule; no patients with two pure ground glass nodules had nodal metastasis. •NGS testing was feasible and adequate on the majority of samples, aiding clinicians in staging multifocal nodules. This abstract is funded by: None